Liu Shuai, Gao Yuchen, Luo Jun, Chen Yanhua, Cao Heng, Guo Zhuifeng, Zhou Hongmin, Hong Zhongwen, Chen Bowen, Xu Xiao, Zhang Jingcheng, Duan Nengliang, Zhan Xiangcheng, Yao Xudong, Xie Tiancheng, Dong Yunze, Xu Yunfei
Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Urology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Ren Fail. 2025 Dec;47(1):2521456. doi: 10.1080/0886022X.2025.2521456. Epub 2025 Jun 29.
Urolithiasis is one of the most common urological diseases, and its incidence has increased globally in recent years. Multiple potential mechanisms are involved in urolithiasis, including renal oxidative stress, inflammatory response, fibrosis, pyroptosis, and gut microbiota disturbance. Sodium bicarbonate (NaHCO) is commonly used clinically to alkalize urine and slow the progression of chronic kidney disease, including urolithiasis. However, the specific mechanism of NaHCO in the treatment of urolithiasis is unclear.
In this study, we constructed a mice urolithiasis model intraperitoneal injection of glyoxylate (50 mg/kg) for one week in C57BL/6 mice. Meanwhile, 5% NaHCO was added to drinking water in the treatment group. Biochemical detection, immunohistochemical staining, RT-qPCR, and Western blotting were used to assess kidney function and levels of inflammation and pyroptosis. The alteration of gut microbiota in mice treated with NaHCO was measured using 16S rDNA sequencing.
The results demonstrated that NaHCO effectively reduced the deposition of CaOx crystal, as well as restored kidney function in urolithiasis-induced kidney injury mice. Moreover, NaHCO alleviated oxidative stress and inflammatory response and ameliorated pyroptosis by modulating the NLRP3 inflammasome pathway in kidney. Additionally, it enhanced the intestinal barrier function by up-regulating the expression of tight junction proteins (ZO-1, occludin, and claudin 5), remodeling the gut microbiota, and reducing intestinal inflammation.
In summary, NaHCO exerted a protective effect the gut-kidney axis in the urolithiasis mice model, suggesting its potential use as a dietary supplementation to be added to daily drinking water for the management of urolithiasis.
尿石症是最常见的泌尿系统疾病之一,近年来其发病率在全球范围内呈上升趋势。尿石症涉及多种潜在机制,包括肾脏氧化应激、炎症反应、纤维化、细胞焦亡和肠道微生物群紊乱。碳酸氢钠(NaHCO)在临床上常用于碱化尿液并减缓包括尿石症在内的慢性肾脏病的进展。然而,NaHCO治疗尿石症的具体机制尚不清楚。
在本研究中,我们通过给C57BL/6小鼠腹腔注射乙醛酸(50mg/kg)一周构建小鼠尿石症模型。同时,治疗组在饮水中添加5%的NaHCO。采用生化检测、免疫组织化学染色、RT-qPCR和蛋白质免疫印迹法评估肾功能以及炎症和细胞焦亡水平。使用16S rDNA测序检测用NaHCO处理的小鼠肠道微生物群的变化。
结果表明,NaHCO有效减少了草酸钙晶体的沉积,并恢复了尿石症诱导的肾损伤小鼠的肾功能。此外,NaHCO通过调节肾脏中的NLRP3炎性小体途径减轻氧化应激和炎症反应,并改善细胞焦亡。此外,它通过上调紧密连接蛋白(ZO-1、闭合蛋白和claudin 5)的表达、重塑肠道微生物群和减轻肠道炎症来增强肠道屏障功能。
总之,NaHCO在尿石症小鼠模型中对肠-肾轴发挥了保护作用,表明其有可能作为膳食补充剂添加到日常饮水中用于管理尿石症。